India could have a fourth Covid vaccine by August with Hyderabad-based Biological E’s candidate having completed its phase one and two trials and about to enter stage three, V K Paul, member-health, NITI Aayog, told reporters on Wednesday. Besides, Covishield and Covaxin, which are available in India, regulator Drugs Controller General of India (DCGI) has also approved Russia’s Sputnik V. Paul said that the vaccine was being developed with the help of the department of biotechnology and the company has a capacity to make around 70 million doses per month. “It is a significant development. They are old manufacturers of children’s vaccines and have a major capacity,” Paul said, adding that Biological E will be submitting data of phase one and two clinical trials soon.